Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody-Reference-Cited by-同舟云学术

Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody

Published:2016-05-13 Issue:6287 Volume:352 Page:828-833
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Kong Rui¹,Xu Kai¹,Zhou Tongqing¹,Acharya Priyamvada¹,Lemmin Thomas²,Liu Kevin¹,Ozorowski Gabriel³⁴⁵,Soto Cinque¹,Taft Justin D.¹,Bailer Robert T.¹,Cale Evan M.¹,Chen Lei¹,Choi Chang W.¹,Chuang Gwo-Yu¹,Doria-Rose Nicole A.¹,Druz Aliaksandr¹,Georgiev Ivelin S.¹,Gorman Jason¹,Huang Jinghe⁶,Joyce M. Gordon¹,Louder Mark K.¹,Ma Xiaochu⁷,McKee Krisha¹,O’Dell Sijy¹,Pancera Marie¹,Yang Yongping¹,Blanchard Scott C.⁸,Mothes Walther⁷,Burton Dennis R.⁹¹⁰,Koff Wayne C.¹¹,Connors Mark⁶,Ward Andrew B.³⁴⁵,Kwong Peter D.¹,Mascola John R.¹

Affiliation:

1. Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

2. Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.

3. Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

4. Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA.

5. International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.

6. HIV-Specific Immunity Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

7. Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT 06536, USA.

8. Department of Physiology and Biophysics, Weill Cornell Medical College of Cornell University, New York, NY 10021, USA.

9. Department of Immunology and Microbial Science, International AIDS Vaccine Initiative Neutralizing Antibody Center, Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA.

10. Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Boston, MA 02142, USA.

11. International AIDS Vaccine Initiative, New York, NY 10038, USA.

Abstract

An antibody to block viral fusion A small fraction of HIV-1–infected individuals develop broad and potent antibodies that bind the HIV-1 envelope protein (Env). These antibodies recognize a limited set of conserved epitopes on Env, such as Env's host receptor-binding site. Kong et al. now report a neutralizing antibody isolated from an HIV-1–infected individual that binds to the fusion peptide of Env. This is unexpected because viruses often try to mask such key components of their cell entry machinery from antibody attack. Crystal structures of the antibody bound to the fusion peptide and to Env itself define the epitope, provide insight into the specific mechanism of antibody binding, and may inform HIV-1 vaccine design. Science , this issue p. 828

Funder

NIH

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference53 articles.

1. The structural biology of type I viral membrane fusion

2. Mechanisms of Viral Membrane Fusion and Its Inhibition

3. Viral membrane fusion

4. Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer

5. Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer

Cited by 309 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fc‐FcγR interactions during infections: From neutralizing antibodies to antibody‐dependent enhancement;Immunological Reviews;2024-09-13

2. Conformational flexibility of HIV-1 envelope glycoproteins modulates transmitted/founder sensitivity to broadly neutralizing antibodies;Nature Communications;2024-08-26

3. Insertion and Anchoring of HIV-1 Fusion Peptide into Complex Membrane Mimicking Human T-cell;2024-08-04

4. The S2 subunit of spike encodes diverse targets for functional antibody responses to SARS-CoV-2;PLOS Pathogens;2024-08-02

5. Priming antibody responses to the fusion peptide in rhesus macaques;npj Vaccines;2024-07-12